Jonathan Tobin
Managing Director @ Arix Bioscience
London, United Kingdom
Jonathan Tobin is a Series A investor at Arix Bioscience in London focused on Biotechnology and Therapeutics. Jonathan specialises in therapeutics and diagnostics investments and has a background in medical research and drug discovery. Prior to joining Imperial Innovations he worked at MRC Technology, sourcing and evaluating new opportunities for small molecule and antibody drug discovery worldwide. He has a PhD in molecular medicine from UCL, andundertook post-doctoral research at the Cancer Research UK LRI. He has published in journals including New England Journal of Medicine, Nature Genetics, and PNAS. Jonathan has a First Class degree in Biological Science from Oxford University and an MBA with Distinction from Imperial College.
- Total investments:
- 10
- Last investment:
- Lead investor:
- 30%
Last updated:
For AI agents: llms.txt
Industries Jonathan Tobin invests in
Stages Jonathan Tobin invests in
Countries Jonathan Tobin invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Biotechnology 5 (50%)
- Therapeutics 3 (30%)
- Life Science 2 (20%)
- Medical 1 (10%)
- Pharmaceutical 1 (10%)
Stage
- Series A 5 (50%)
- Series B 2 (20%)
- Series C 1 (10%)
- Series D 1 (10%)
- Series F 1 (10%)
Country
- United Kingdom 4 (40%)
- Israel 1 (10%)
- Germany 1 (10%)
- United States 1 (10%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
NRG Therapeutics
|
NRG Therapeutics is a drug discovery company focussed on therapeutic approaches that will restore mitochondrial function and slow or halt the progression of neurodegenerative diseases such as Parkinson’s disease, Alzheimer’s disease and motor neurone disease. Founded in 2018 by a team of experienced biotech and pharmaceutical industryprofessionals, with a background in neuroscience drug discovery, NRG Therapeutics will initially focus on the discovery and development of brain penetrant mitochondrial permeability transition pore inhibitors for the treatment of Parkinson’s disease. | $67.8M / Series B / Sep 08, 2025 | |
CatalYm
|
Catalym develops antibodies against a placental factor which is overexpressed by various tumour types. | $150M / Series D / Jul 16, 2024 | |
Myricx Bio
|
Myricx Pharma is a small molecule drug discovery company engaged in developing novel proprietary inhibitors of human N-myristoyltransferases (NMT), with a primary focus in oncology but also exploring potential applications across other diseases. | $115.3M / Series A / Jul 08, 2024 | |
Pheon Therapeutics
|
Pheon Therapeutics is an Antibody-Drug Conjugate (ADC) specialist that creates ADCs for a variety of difficult-to-treat cancers. Its lead program is a first-in-class ADC against a novel target that is highly expressed in solid tumors across a broad range of hard-to-treat cancer types.The company was founded in 2022 and is based in London,England. | $120M / Series B / May 21, 2024 | |
AstronauTx
|
AstronauTx is a UCL spin-off, will develop medicines designed to reset the behaviour of astrocytes. | $58.7M / Series A / Oct 08, 2023 | |
|
CatalYm
|
Catalym develops antibodies against a placental factor which is overexpressed by various tumour types. | $51.6M / Series C / Nov 22, 2022 | |
|
NRG Therapeutics
|
NRG Therapeutics is a drug discovery company focussed on therapeutic approaches that will restore mitochondrial function and slow or halt the progression of neurodegenerative diseases such as Parkinson’s disease, Alzheimer’s disease and motor neurone disease. Founded in 2018 by a team of experienced biotech and pharmaceutical industryprofessionals, with a background in neuroscience drug discovery, NRG Therapeutics will initially focus on the discovery and development of brain penetrant mitochondrial permeability transition pore inhibitors for the treatment of Parkinson’s disease. | $18.2M / Series A / Nov 09, 2022 | |
|
Pheon Therapeutics
|
Pheon Therapeutics is an Antibody-Drug Conjugate (ADC) specialist that creates ADCs for a variety of difficult-to-treat cancers. Its lead program is a first-in-class ADC against a novel target that is highly expressed in solid tumors across a broad range of hard-to-treat cancer types.The company was founded in 2022 and is based in London,England. | $68M / Series A / Sep 28, 2022 | |
Quench Bio
|
Quench Bio is a developer of gasdermin biology drugs designed to treat severe inflammatory diseases.The company leverages insights into gasdermin biology and innate immunity to develop medicines with lead compounds that target and inhibit the pore-forming protein that mediates the release of inflammatory cytokines, alarmins, DNA and NETs, enablingpatients to get relief from inflammatory diseases. | Series A / Jan 27, 2020 | |
Atox Bio
|
Atox Bio is a biotechnology company that specializes in infectious diseases, immunomodulators, and critical care.It focuses on novel modulators of the immune response that target key multiple and interrelated pathways of both the adaptive and innate immune response that play critical roles in infectious and inflammatory diseases as well asischemia/reperfusion injuries.The company was founded in 2003 and headquartered in HaMerkaz, Israel. | $30M / Series F / Dec 04, 2017 |
Co-Investors
About Arix Bioscience
Arix Bioscience is a global healthcare and life science company that drives value in private and public companies through operational and strategic direction as well as patient capital Their extensive experience in academic science, clinical and commercial strategy, company operations, mergers and acquisitions, venture capital and corporate financeputs them in an especially strong position to build and support a wide range of businesses and technologies.Arix Bioscience has privileged agreements with leading universities in the UK, Europe and Australia, providing direct access to innovative new technologies. They also have access to a broad range of research projects from US academic institutions.
Arix Bioscience Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Daniel O'Connell
Investment Manager
|
|||
James Rawlingson
Chief Financial Officer
|
|||
|
Jonathan Tobin
Managing Director
|
|||
Chris Evans
Deputy Chairman
|
|||
Chris Evans
Deputy Chairman
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Jonathan Tobin invest in?
Jonathan Tobin invests primarily in Biotechnology, Therapeutics and Life Science startups, most often at Series A and Series B stage. Most of the 10 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Jonathan Tobin?
Public channels for Jonathan Tobin include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Jonathan Tobin last invest?
The most recent investment recorded for Jonathan Tobin closed in Sep 2025. Shizune tracks 10 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
